Business
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement financing. The Company's...
About this update from Izotropic Corp.
[{"type":"text","content":"Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement financing.","length":502,"tagName":"p"},{"type":"text","content":"The Company's primary objective is securing capital financing to fund the commercialization of IzoView Breast CT, including prioritizing non-dilutive options, while actively evaluating opportunities to expedite additional regulatory pathways and positioning for earlier revenue generation.","length":293,"tagName":"p"},{"type":"text","content":"These efforts may include the investigation and continued development of strategic relationships that have advanced to due diligence stages, with the objective of executing letters of intent and definitive agreements. Such arrangements may include the formation and advancement of global business units, territory and manufacturing rights, master distribution agreements, and the management of accelerated regulatory procedures and approvals in additional markets.","length":464,"tagName":"p"},{"type":"text","content":"To support funding and relationship development, the Company has presented, and continues to present, its business plan and integrated seven-year financial model addressing all major aspects of operations and commercialization, including regulatory strategies across multiple jurisdictions; go-to-market planning; marketing and sales initiatives; distribution and sales models; diversified revenue streams; uplisting considerations; capital structure considerations, including debt settlements and equity conversions; expanded Indications for Use for IzoView; development and commercialization of a second medical device; intellectual property and competitive positioning; milestone-based commercialization timelines; and risk mitigation strategies. Members of the Company's Board of Directors and Advisory Board are actively participating in these meetings and leading presentations.","length":888,"tagName":"p"},{"type":"text","content":...